CD83 BINDING FUSION PROTEINS

Title:

CD83 BINDING FUSION PROTEINS

Document Type and Number:

WIPO Patent Application WO/2024/040220

Kind Code:

A3

Abstract:

Therapeutics which target CD83 show great promise in the treatment and prevention of cancer and immunological disorders. The disclosure provides a fusion protein comprising a CD83 binding domain comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 23, and SEQ ID NO: 24 and an Fc domain, as well as methods of use.

More Like This:

JP2022553390	Novel anti-CD47 antibody and use thereof
WO/1999/041375	HUMAN RECEPTOR PROTEINS
JP4746552	Use of antagonist anti-CD40 antibody for the treatment of autoimmune and inflammatory diseases and organ transplant rejection

Inventors:

BETTS BRIAN (US)
LEBEAU AARON (US)
ROBERTSON AUSTIN (US)

Application Number:

PCT/US2023/072466

Publication Date:

May 16, 2024

Filing Date:

August 18, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV MINNESOTA (US)
WISCONSIN ALUMNI RES FOUND (US)

International Classes:

C07K16/28; A61K38/16; A61K39/395; A61P35/00; A61P37/00

Attorney, Agent or Firm:

KISSLING, Heather, R. et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SYSTEMS AND METHODS FOR CONTROLLING A SURGICAL PUMP USING ENDOSCOPIC VIDEO DATA

Next Patent: MODULAR WELL PLATE SYSTEM WITH A REUSABLE FRAME